Lyophilisation

Famar R&D is offering a complete set of Contract Development services.

• Formulation and process development for Rx, Gx, OTC, Cosmetics (Solids, Semi-solids /liquids dosage forms, Sterile liquids & Lyophilized powders) and Medical Devices • Analytical methods development and validation&nbs...

Famar has a legacy of more than 70 years in Contract Manufacturing. Through a network of 6 production sites in Europe, we provide manufacturing capability for a broad range of dosage forms, for Rx, OTC and Health& Beauty products, in the following forms: 
• Solid forms • Semi-solid and Li...

Famar offers pharmaceutical services which includes nasal sprays. It belongs to liquid forms category. 

Contact us for more information!

Famar offers pharmaceutical services which includes drops. It belongs to liquid forms category. 

Contact us for more information!

Medicom Healthcare Limited (Medicom) and Famar Health Care Services Madrid (Famar) are pleased to announce the signing of an Asset Purchase Agreement (APA) for the acquisition by Medicom of the pharmaceutical dossier of BIMATOPROST 0.3 mg/mL, 3ml, preservative free eye drop solution, developed by Famar R&D. Medicom and Famar have also entered into a long term Manufacturing and Supply Agreement (MSA) with Famar being the exclusive manufacturer of this product.

This video highlights our recognized and awarded CDMO leadership in the categories of Service, Quality, Capabilities, Expertise, Reliability and Compatibility.Watch the video for a glance at our company's culture and working principles and how we integrate all our skills together to meet the needs of our customers.

The coronavirus pandemic has been incredibly disruptive for all facets of life around the globe, exerting extreme pressure on practically all industry sectors and severely impacting the usual day-to-day interactions they have become accustomed to. The pharmaceutical industry has been thrust into the vanguard of this global crisis, not only in its quest to find effective vaccines or therapeutics to fight the virus but also in its responsibility to continue to manufacture life-changing and essential medicines and ensure they are delivered to patients. Even before the pandemic struck, pharma and biotech have been steadily increasing their outsourcing to contract development and manufacturing organisations (CDMOs) not only to cut costs and have access to manufacturing capacity but also to better deploy their resources and gain access to expertise in other phases of the product lifecycle. This podcast was originally aired as part of the CPHI Festival of Pharma.